Internalizing anti-CD74 antibodies and methods of use
AssigneeImmunomedics, Inc.
InventorsHans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
Claims23
A humanized, or chimeric anti-CD74 antibody or CD74 antigen-binding fragment thereof comprising the light chain variable region complementarity-determining region (CDR) sequences CDR1 (RSSQSLVHRNGNTYLH;
- SEQ ID NO:19), CDR2 (TVSNRFS;
- SEQ ID NO:20), and CDR3 (SQSSHVPPT;
- SEQ ID NO:21) and the heavy chain variable region CDR sequences CDR1 (NYGVN;
- SEQ ID NO:22), CDR2 (WINPNTGEPTFDDDFKG;
- SEQ ID NO:23), and CDR3 (SRGKNEAWFAY;
- SEQ ID NO:24).
A murine anti-CD74 monoclonal antibody (mAb) or antigen-binding fragment thereof comprising:
- (a) CDRs of a light chain variable region of a murine anti-CD74 mAb, that comprises CDR1 (RSSQSLVHRNGNTYLH, SEQ ID NO:19), CDR2 (TVSNRFS, SEQ ID NO:20), and CDR3 (SQSSHVPPT, SEQ ID NO:21);
- (b) CDRs of a heavy chain variable region of a murine anti-CD74 mAb, that comprises CDR1 (NYGVN, SEQ ID NO:22), CDR2 (WINPNTGEPTFDDDFKG, (SEQ ID NO:23), and CDR3 (SRGKNEAWFAY, SEQ ID NO:24);
- and
- (c) the framework (FR) regions of a murine anti-CD74 antibody.
Dependencies are inferred from the claim text.